Pancreatic Cancer Pill Doubles Patient Survival Time

For the first time ever, a single pill is doubling how long pancreatic cancer patients survive, and scientists are calling it the most meaningful shift in treatment history.

The drug daraxonrasib targets KRAS mutations, which drive most pancreatic cancers. For decades, researchers believed KRAS was "undruggable," but sustained investment in the science has finally paid off with results that have never been seen before in this disease.

The Pancreatic Cancer Action Network (PanCAN) has invested approximately $17 million in KRAS research across 39 investigators and 45 grants over 25 years. That long-term commitment helped create the scientific foundation that made this breakthrough possible.

Dr. Anna Berkenblit, PanCAN's Chief Scientific and Medical Officer, says she can't think of a more exciting time for pancreatic cancer research. The benefit to patients is profound, especially since pancreatic cancer remains one of the world's deadliest cancers.

Daraxonrasib isn't the only promising development. Researchers are also making progress with personalized mRNA vaccines that could help patients in the early stages of disease by tailoring treatment to each person's unique tumor and immune system.

These two approaches represent different ends of the treatment spectrum. One aims to help many patients with advanced disease using a simple pill, while the other creates individualized treatments for early-stage patients.

The Ripple Effect: Together, these advances show that pancreatic cancer research is finally moving forward on multiple fronts simultaneously. Progress isn't coming from one single cure but from many advances happening at once, including better targeted therapies, more personalized treatment strategies, earlier detection, and greater access to clinical trials.

The breakthrough reflects years of work by researchers, patients who participated in clinical trials, and advocates who pushed for greater urgency. In May, PanCAN leaders met with the National Cancer Institute's new director and visited Capitol Hill with pancreatic cancer researchers to emphasize how critical continued federal funding is for advancing new therapies.

While daraxonrasib and the mRNA vaccine are still being studied and not yet standard treatments, they represent the kind of sustained scientific momentum the field has desperately needed. For patients and families facing this disease today, real progress is finally within reach.